2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
3147
Neoplasms
2478
Carcinoma, Non-Small-Cell Lung
1889
Prostatic Neoplasms
1645
Colorectal Neoplasms
1438
Lung Neoplasms
1312
Multiple Myeloma
940
Neoplasm Metastasis
930
Leukemia, Myeloid, Acute
885
Pancreatic Neoplasms
862
Ovarian Neoplasms
815
Melanoma
794
Carcinoma, Hepatocellular
745
Stomach Neoplasms
650
Brain Neoplasms
643
Recurrence
642
Squamous Cell Carcinoma of Head and Neck
639
Head and Neck Neoplasms
613
Glioblastoma
575
Lymphoma
551
Uterine Cervical Neoplasms
549
Triple Negative Breast Neoplasms
515
Precursor Cell Lymphoblastic Leukemia-Lymphoma
511
Carcinoma, Renal Cell
505
Endometrial Neoplasms
467
Hematologic Neoplasms
466
Urinary Bladder Neoplasms
462
Colonic Neoplasms
448
Sarcoma
439
Lymphoma, Non-Hodgkin
439
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled